First Time Loading...

Fate Therapeutics Inc
NASDAQ:FATE

Watchlist Manager
Fate Therapeutics Inc Logo
Fate Therapeutics Inc
NASDAQ:FATE
Watchlist
Price: 3.53 USD 0.28%
Updated: May 28, 2024

Fate Therapeutics Inc
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Fate Therapeutics Inc
Cash & Cash Equivalents Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Fate Therapeutics Inc
NASDAQ:FATE
Cash & Cash Equivalents
$121.3m
CAGR 3-Years
4%
CAGR 5-Years
-8%
CAGR 10-Years
10%
Abbvie Inc
NYSE:ABBV
Cash & Cash Equivalents
$18.1B
CAGR 3-Years
23%
CAGR 5-Years
30%
CAGR 10-Years
8%
Gilead Sciences Inc
NASDAQ:GILD
Cash & Cash Equivalents
$4.7B
CAGR 3-Years
5%
CAGR 5-Years
-23%
CAGR 10-Years
-3%
Amgen Inc
NASDAQ:AMGN
Cash & Cash Equivalents
$9.7B
CAGR 3-Years
17%
CAGR 5-Years
6%
CAGR 10-Years
10%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash & Cash Equivalents
$9.2B
CAGR 3-Years
13%
CAGR 5-Years
26%
CAGR 10-Years
36%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash & Cash Equivalents
$2.6B
CAGR 3-Years
22%
CAGR 5-Years
9%
CAGR 10-Years
19%

See Also

What is Fate Therapeutics Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
121.3m USD

Based on the financial report for Mar 31, 2024, Fate Therapeutics Inc's Cash & Cash Equivalents amounts to 121.3m USD.

What is Fate Therapeutics Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
10%

Over the last year, the Cash & Cash Equivalents growth was 189%. The average annual Cash & Cash Equivalents growth rates for Fate Therapeutics Inc have been 4% over the past three years , -8% over the past five years , and 10% over the past ten years .